nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—PTK2—malignant glioma	0.424	0.779	CbGaD
Bosutinib—EGFR—malignant glioma	0.121	0.222	CbGaD
Bosutinib—Gastrointestinal toxicity—Carmustine—malignant glioma	0.00592	0.105	CcSEcCtD
Bosutinib—Traumatic liver injury—Temozolomide—malignant glioma	0.00252	0.0445	CcSEcCtD
Bosutinib—Myelosuppression—Carmustine—malignant glioma	0.00207	0.0366	CcSEcCtD
Bosutinib—Myelosuppression—Temozolomide—malignant glioma	0.002	0.0354	CcSEcCtD
Bosutinib—Febrile neutropenia—Carmustine—malignant glioma	0.00162	0.0285	CcSEcCtD
Bosutinib—Febrile neutropenia—Temozolomide—malignant glioma	0.00156	0.0276	CcSEcCtD
Bosutinib—Hepatotoxicity—Carmustine—malignant glioma	0.00126	0.0222	CcSEcCtD
Bosutinib—Hepatotoxicity—Temozolomide—malignant glioma	0.00122	0.0215	CcSEcCtD
Bosutinib—Vandetanib—KDR—malignant glioma	0.00116	0.308	CrCbGaD
Bosutinib—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00114	0.0202	CcSEcCtD
Bosutinib—Liver injury—Temozolomide—malignant glioma	0.00112	0.0197	CcSEcCtD
Bosutinib—Vandetanib—VEGFA—malignant glioma	0.00098	0.261	CrCbGaD
Bosutinib—Respiratory failure—Temozolomide—malignant glioma	0.000956	0.0169	CcSEcCtD
Bosutinib—Vandetanib—EGFR—malignant glioma	0.000826	0.221	CrCbGaD
Bosutinib—Gefitinib—EGFR—malignant glioma	0.000785	0.21	CrCbGaD
Bosutinib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000705	0.0125	CcSEcCtD
Bosutinib—Face oedema—Carmustine—malignant glioma	0.000681	0.012	CcSEcCtD
Bosutinib—Face oedema—Temozolomide—malignant glioma	0.000658	0.0116	CcSEcCtD
Bosutinib—Dehydration—Temozolomide—malignant glioma	0.000634	0.0112	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000614	0.0108	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000601	0.0106	CcSEcCtD
Bosutinib—Pancytopenia—Carmustine—malignant glioma	0.000579	0.0102	CcSEcCtD
Bosutinib—Neutropenia—Carmustine—malignant glioma	0.00057	0.0101	CcSEcCtD
Bosutinib—Bronchitis—Temozolomide—malignant glioma	0.000567	0.01	CcSEcCtD
Bosutinib—Pancytopenia—Temozolomide—malignant glioma	0.000559	0.00989	CcSEcCtD
Bosutinib—Neutropenia—Temozolomide—malignant glioma	0.000551	0.00974	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000548	0.00968	CcSEcCtD
Bosutinib—Pneumonia—Carmustine—malignant glioma	0.000547	0.00966	CcSEcCtD
Bosutinib—Renal failure—Carmustine—malignant glioma	0.000534	0.00944	CcSEcCtD
Bosutinib—Pneumonia—Temozolomide—malignant glioma	0.000528	0.00934	CcSEcCtD
Bosutinib—Infestation—Temozolomide—malignant glioma	0.000525	0.00928	CcSEcCtD
Bosutinib—Infestation NOS—Temozolomide—malignant glioma	0.000525	0.00928	CcSEcCtD
Bosutinib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000497	0.00878	CcSEcCtD
Bosutinib—Oedema peripheral—Carmustine—malignant glioma	0.000481	0.0085	CcSEcCtD
Bosutinib—Connective tissue disorder—Carmustine—malignant glioma	0.00048	0.00847	CcSEcCtD
Bosutinib—Hepatitis—Temozolomide—malignant glioma	0.000472	0.00833	CcSEcCtD
Bosutinib—Urinary tract disorder—Temozolomide—malignant glioma	0.000466	0.00823	CcSEcCtD
Bosutinib—Oedema peripheral—Temozolomide—malignant glioma	0.000465	0.00821	CcSEcCtD
Bosutinib—Connective tissue disorder—Temozolomide—malignant glioma	0.000463	0.00819	CcSEcCtD
Bosutinib—Urethral disorder—Temozolomide—malignant glioma	0.000462	0.00817	CcSEcCtD
Bosutinib—Erythema multiforme—Temozolomide—malignant glioma	0.000446	0.00788	CcSEcCtD
Bosutinib—Tinnitus—Temozolomide—malignant glioma	0.00044	0.00777	CcSEcCtD
Bosutinib—Cardiac disorder—Temozolomide—malignant glioma	0.000438	0.00773	CcSEcCtD
Bosutinib—Immune system disorder—Temozolomide—malignant glioma	0.000426	0.00753	CcSEcCtD
Bosutinib—Mediastinal disorder—Temozolomide—malignant glioma	0.000425	0.00751	CcSEcCtD
Bosutinib—Malnutrition—Carmustine—malignant glioma	0.000425	0.00751	CcSEcCtD
Bosutinib—Back pain—Carmustine—malignant glioma	0.000411	0.00726	CcSEcCtD
Bosutinib—Malnutrition—Temozolomide—malignant glioma	0.000411	0.00725	CcSEcCtD
Bosutinib—Dysgeusia—Temozolomide—malignant glioma	0.000402	0.0071	CcSEcCtD
Bosutinib—Back pain—Temozolomide—malignant glioma	0.000397	0.00702	CcSEcCtD
Bosutinib—Anaemia—Carmustine—malignant glioma	0.000393	0.00694	CcSEcCtD
Bosutinib—Ill-defined disorder—Temozolomide—malignant glioma	0.000381	0.00673	CcSEcCtD
Bosutinib—Leukopenia—Carmustine—malignant glioma	0.00038	0.00672	CcSEcCtD
Bosutinib—Anaemia—Temozolomide—malignant glioma	0.000379	0.00671	CcSEcCtD
Bosutinib—Malaise—Temozolomide—malignant glioma	0.00037	0.00654	CcSEcCtD
Bosutinib—Leukopenia—Temozolomide—malignant glioma	0.000367	0.00649	CcSEcCtD
Bosutinib—Chest pain—Carmustine—malignant glioma	0.000362	0.00639	CcSEcCtD
Bosutinib—Myalgia—Carmustine—malignant glioma	0.000362	0.00639	CcSEcCtD
Bosutinib—Cough—Temozolomide—malignant glioma	0.000358	0.00633	CcSEcCtD
Bosutinib—Arthralgia—Temozolomide—malignant glioma	0.000349	0.00618	CcSEcCtD
Bosutinib—Myalgia—Temozolomide—malignant glioma	0.000349	0.00618	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000347	0.00613	CcSEcCtD
Bosutinib—Oedema—Carmustine—malignant glioma	0.000347	0.00613	CcSEcCtD
Bosutinib—Discomfort—Temozolomide—malignant glioma	0.000345	0.0061	CcSEcCtD
Bosutinib—Infection—Carmustine—malignant glioma	0.000344	0.00609	CcSEcCtD
Bosutinib—Thrombocytopenia—Carmustine—malignant glioma	0.000339	0.006	CcSEcCtD
Bosutinib—Anaphylactic shock—Temozolomide—malignant glioma	0.000335	0.00592	CcSEcCtD
Bosutinib—Oedema—Temozolomide—malignant glioma	0.000335	0.00592	CcSEcCtD
Bosutinib—Infection—Temozolomide—malignant glioma	0.000333	0.00588	CcSEcCtD
Bosutinib—Nervous system disorder—Temozolomide—malignant glioma	0.000329	0.00581	CcSEcCtD
Bosutinib—Thrombocytopenia—Temozolomide—malignant glioma	0.000328	0.0058	CcSEcCtD
Bosutinib—Skin disorder—Temozolomide—malignant glioma	0.000325	0.00575	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000316	0.00558	CcSEcCtD
Bosutinib—Dyspnoea—Carmustine—malignant glioma	0.000309	0.00546	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000305	0.00539	CcSEcCtD
Bosutinib—Decreased appetite—Carmustine—malignant glioma	0.000301	0.00533	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000299	0.00529	CcSEcCtD
Bosutinib—Dyspnoea—Temozolomide—malignant glioma	0.000299	0.00528	CcSEcCtD
Bosutinib—Pain—Carmustine—malignant glioma	0.000296	0.00524	CcSEcCtD
Bosutinib—Decreased appetite—Temozolomide—malignant glioma	0.000291	0.00515	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000289	0.00511	CcSEcCtD
Bosutinib—Fatigue—Temozolomide—malignant glioma	0.000289	0.0051	CcSEcCtD
Bosutinib—Pain—Temozolomide—malignant glioma	0.000286	0.00506	CcSEcCtD
Bosutinib—Feeling abnormal—Carmustine—malignant glioma	0.000286	0.00505	CcSEcCtD
Bosutinib—Gastrointestinal pain—Carmustine—malignant glioma	0.000283	0.00501	CcSEcCtD
Bosutinib—Feeling abnormal—Temozolomide—malignant glioma	0.000276	0.00488	CcSEcCtD
Bosutinib—Abdominal pain—Carmustine—malignant glioma	0.000274	0.00484	CcSEcCtD
Bosutinib—Body temperature increased—Carmustine—malignant glioma	0.000274	0.00484	CcSEcCtD
Bosutinib—Gastrointestinal pain—Temozolomide—malignant glioma	0.000274	0.00484	CcSEcCtD
Bosutinib—Urticaria—Temozolomide—malignant glioma	0.000266	0.0047	CcSEcCtD
Bosutinib—Abdominal pain—Temozolomide—malignant glioma	0.000265	0.00468	CcSEcCtD
Bosutinib—Body temperature increased—Temozolomide—malignant glioma	0.000265	0.00468	CcSEcCtD
Bosutinib—Asthenia—Carmustine—malignant glioma	0.000249	0.0044	CcSEcCtD
Bosutinib—TBK1—medulla oblongata—malignant glioma	0.000244	0.00175	CbGeAlD
Bosutinib—MAP3K19—central nervous system—malignant glioma	0.000242	0.00174	CbGeAlD
Bosutinib—LRRK2—spinal cord—malignant glioma	0.000242	0.00174	CbGeAlD
Bosutinib—FER—cerebellum—malignant glioma	0.000242	0.00174	CbGeAlD
Bosutinib—EPHA5—cerebellum—malignant glioma	0.000242	0.00174	CbGeAlD
Bosutinib—TYRO3—cerebellum—malignant glioma	0.000242	0.00174	CbGeAlD
Bosutinib—Asthenia—Temozolomide—malignant glioma	0.00024	0.00425	CcSEcCtD
Bosutinib—SRC—telencephalon—malignant glioma	0.00024	0.00173	CbGeAlD
Bosutinib—CSNK1E—midbrain—malignant glioma	0.000238	0.00171	CbGeAlD
Bosutinib—TNK2—central nervous system—malignant glioma	0.000238	0.00171	CbGeAlD
Bosutinib—Diarrhoea—Carmustine—malignant glioma	0.000237	0.00419	CcSEcCtD
Bosutinib—Pruritus—Temozolomide—malignant glioma	0.000237	0.00419	CcSEcCtD
Bosutinib—CHEK2—brain—malignant glioma	0.000236	0.0017	CbGeAlD
Bosutinib—PDGFRB—embryo—malignant glioma	0.000235	0.00169	CbGeAlD
Bosutinib—RPS6KB1—medulla oblongata—malignant glioma	0.000234	0.00169	CbGeAlD
Bosutinib—WEE1—brain—malignant glioma	0.000234	0.00168	CbGeAlD
Bosutinib—DMPK—brain—malignant glioma	0.000234	0.00168	CbGeAlD
Bosutinib—CSNK1E—spinal cord—malignant glioma	0.000232	0.00167	CbGeAlD
Bosutinib—TNK2—cerebellum—malignant glioma	0.000232	0.00167	CbGeAlD
Bosutinib—AXL—medulla oblongata—malignant glioma	0.000232	0.00167	CbGeAlD
Bosutinib—ERBB4—central nervous system—malignant glioma	0.000231	0.00166	CbGeAlD
Bosutinib—ERBB3—midbrain—malignant glioma	0.00023	0.00165	CbGeAlD
Bosutinib—Dizziness—Carmustine—malignant glioma	0.000229	0.00405	CcSEcCtD
Bosutinib—Diarrhoea—Temozolomide—malignant glioma	0.000229	0.00405	CcSEcCtD
Bosutinib—MAP2K2—midbrain—malignant glioma	0.000229	0.00165	CbGeAlD
Bosutinib—ULK3—midbrain—malignant glioma	0.000229	0.00165	CbGeAlD
Bosutinib—MAP4K2—cerebellum—malignant glioma	0.000229	0.00165	CbGeAlD
Bosutinib—SIK1—spinal cord—malignant glioma	0.000229	0.00164	CbGeAlD
Bosutinib—IRAK4—spinal cord—malignant glioma	0.000229	0.00164	CbGeAlD
Bosutinib—ROCK1—central nervous system—malignant glioma	0.000228	0.00164	CbGeAlD
Bosutinib—STK3—cerebellum—malignant glioma	0.000226	0.00162	CbGeAlD
Bosutinib—ERBB4—cerebellum—malignant glioma	0.000226	0.00162	CbGeAlD
Bosutinib—MAP3K7—midbrain—malignant glioma	0.000225	0.00162	CbGeAlD
Bosutinib—ERBB3—spinal cord—malignant glioma	0.000224	0.00161	CbGeAlD
Bosutinib—ULK3—spinal cord—malignant glioma	0.000224	0.00161	CbGeAlD
Bosutinib—MAP2K2—spinal cord—malignant glioma	0.000224	0.00161	CbGeAlD
Bosutinib—SLK—medulla oblongata—malignant glioma	0.000223	0.00161	CbGeAlD
Bosutinib—STK25—brain—malignant glioma	0.000223	0.00161	CbGeAlD
Bosutinib—PTK2—midbrain—malignant glioma	0.000223	0.0016	CbGeAlD
Bosutinib—TBK1—midbrain—malignant glioma	0.000223	0.0016	CbGeAlD
Bosutinib—EPHB4—medulla oblongata—malignant glioma	0.000222	0.0016	CbGeAlD
Bosutinib—EPHA3—brain—malignant glioma	0.000222	0.00159	CbGeAlD
Bosutinib—BMPR2—central nervous system—malignant glioma	0.000222	0.00159	CbGeAlD
Bosutinib—Dizziness—Temozolomide—malignant glioma	0.000222	0.00392	CcSEcCtD
Bosutinib—MAP2K5—telencephalon—malignant glioma	0.000221	0.00159	CbGeAlD
Bosutinib—Vomiting—Carmustine—malignant glioma	0.00022	0.0039	CcSEcCtD
Bosutinib—MAP3K7—spinal cord—malignant glioma	0.00022	0.00158	CbGeAlD
Bosutinib—EPHB3—central nervous system—malignant glioma	0.00022	0.00158	CbGeAlD
Bosutinib—STK36—central nervous system—malignant glioma	0.00022	0.00158	CbGeAlD
Bosutinib—Rash—Carmustine—malignant glioma	0.000219	0.00386	CcSEcCtD
Bosutinib—IRAK1—midbrain—malignant glioma	0.000218	0.00157	CbGeAlD
Bosutinib—Dermatitis—Carmustine—malignant glioma	0.000218	0.00386	CcSEcCtD
Bosutinib—TBK1—spinal cord—malignant glioma	0.000217	0.00156	CbGeAlD
Bosutinib—PTK2—spinal cord—malignant glioma	0.000217	0.00156	CbGeAlD
Bosutinib—MERTK—central nervous system—malignant glioma	0.000217	0.00156	CbGeAlD
Bosutinib—FYN—medulla oblongata—malignant glioma	0.000217	0.00156	CbGeAlD
Bosutinib—PLK2—brain—malignant glioma	0.000217	0.00156	CbGeAlD
Bosutinib—Headache—Carmustine—malignant glioma	0.000217	0.00384	CcSEcCtD
Bosutinib—BMPR2—cerebellum—malignant glioma	0.000217	0.00156	CbGeAlD
Bosutinib—SIK3—brain—malignant glioma	0.000216	0.00155	CbGeAlD
Bosutinib—CSF1R—telencephalon—malignant glioma	0.000216	0.00155	CbGeAlD
Bosutinib—STK36—cerebellum—malignant glioma	0.000215	0.00154	CbGeAlD
Bosutinib—EPHB3—cerebellum—malignant glioma	0.000215	0.00154	CbGeAlD
Bosutinib—RPS6KB1—midbrain—malignant glioma	0.000214	0.00154	CbGeAlD
Bosutinib—MAP4K4—central nervous system—malignant glioma	0.000213	0.00153	CbGeAlD
Bosutinib—Vomiting—Temozolomide—malignant glioma	0.000213	0.00376	CcSEcCtD
Bosutinib—MERTK—cerebellum—malignant glioma	0.000212	0.00153	CbGeAlD
Bosutinib—MAP3K3—medulla oblongata—malignant glioma	0.000212	0.00153	CbGeAlD
Bosutinib—MAP4K5—medulla oblongata—malignant glioma	0.000212	0.00153	CbGeAlD
Bosutinib—AXL—midbrain—malignant glioma	0.000212	0.00153	CbGeAlD
Bosutinib—BCR—central nervous system—malignant glioma	0.000212	0.00152	CbGeAlD
Bosutinib—Rash—Temozolomide—malignant glioma	0.000211	0.00373	CcSEcCtD
Bosutinib—Dermatitis—Temozolomide—malignant glioma	0.000211	0.00373	CcSEcCtD
Bosutinib—MAP3K12—central nervous system—malignant glioma	0.00021	0.00151	CbGeAlD
Bosutinib—Headache—Temozolomide—malignant glioma	0.00021	0.00371	CcSEcCtD
Bosutinib—ABL1—embryo—malignant glioma	0.000209	0.00151	CbGeAlD
Bosutinib—RPS6KB1—spinal cord—malignant glioma	0.000209	0.0015	CbGeAlD
Bosutinib—MAP4K4—cerebellum—malignant glioma	0.000208	0.0015	CbGeAlD
Bosutinib—STK4—brain—malignant glioma	0.000208	0.00149	CbGeAlD
Bosutinib—AXL—spinal cord—malignant glioma	0.000207	0.00149	CbGeAlD
Bosutinib—NUAK2—cerebellum—malignant glioma	0.000207	0.00149	CbGeAlD
Bosutinib—BCR—cerebellum—malignant glioma	0.000207	0.00149	CbGeAlD
Bosutinib—MAP2K1—central nervous system—malignant glioma	0.000206	0.00148	CbGeAlD
Bosutinib—STK35—central nervous system—malignant glioma	0.000206	0.00148	CbGeAlD
Bosutinib—Nausea—Carmustine—malignant glioma	0.000206	0.00364	CcSEcCtD
Bosutinib—MAP3K12—cerebellum—malignant glioma	0.000206	0.00148	CbGeAlD
Bosutinib—CAMK1D—brain—malignant glioma	0.000205	0.00148	CbGeAlD
Bosutinib—CSK—central nervous system—malignant glioma	0.000205	0.00147	CbGeAlD
Bosutinib—SLK—midbrain—malignant glioma	0.000204	0.00147	CbGeAlD
Bosutinib—CSNK1A1—central nervous system—malignant glioma	0.000203	0.00146	CbGeAlD
Bosutinib—STK24—brain—malignant glioma	0.000203	0.00146	CbGeAlD
Bosutinib—EPHB4—midbrain—malignant glioma	0.000203	0.00146	CbGeAlD
Bosutinib—HCK—central nervous system—malignant glioma	0.000202	0.00145	CbGeAlD
Bosutinib—CLK1—central nervous system—malignant glioma	0.000202	0.00145	CbGeAlD
Bosutinib—STK35—cerebellum—malignant glioma	0.000201	0.00145	CbGeAlD
Bosutinib—MAP2K1—cerebellum—malignant glioma	0.000201	0.00145	CbGeAlD
Bosutinib—CSK—cerebellum—malignant glioma	0.0002	0.00144	CbGeAlD
Bosutinib—SLK—spinal cord—malignant glioma	0.000199	0.00143	CbGeAlD
Bosutinib—Nausea—Temozolomide—malignant glioma	0.000199	0.00352	CcSEcCtD
Bosutinib—CSNK1A1—cerebellum—malignant glioma	0.000199	0.00143	CbGeAlD
Bosutinib—FYN—midbrain—malignant glioma	0.000199	0.00143	CbGeAlD
Bosutinib—CAMK2G—central nervous system—malignant glioma	0.000198	0.00143	CbGeAlD
Bosutinib—BMP2K—central nervous system—malignant glioma	0.000198	0.00143	CbGeAlD
Bosutinib—EPHB4—spinal cord—malignant glioma	0.000198	0.00142	CbGeAlD
Bosutinib—CLK1—cerebellum—malignant glioma	0.000197	0.00142	CbGeAlD
Bosutinib—LRRK2—central nervous system—malignant glioma	0.000197	0.00141	CbGeAlD
Bosutinib—FER—brain—malignant glioma	0.000196	0.00141	CbGeAlD
Bosutinib—EPHA5—brain—malignant glioma	0.000196	0.00141	CbGeAlD
Bosutinib—ALK—brain—malignant glioma	0.000196	0.00141	CbGeAlD
Bosutinib—TYRO3—brain—malignant glioma	0.000196	0.00141	CbGeAlD
Bosutinib—ABL2—cerebellum—malignant glioma	0.000196	0.00141	CbGeAlD
Bosutinib—YES1—medulla oblongata—malignant glioma	0.000196	0.00141	CbGeAlD
Bosutinib—LYN—brain—malignant glioma	0.000195	0.0014	CbGeAlD
Bosutinib—MAP4K5—midbrain—malignant glioma	0.000194	0.0014	CbGeAlD
Bosutinib—MAP3K3—midbrain—malignant glioma	0.000194	0.0014	CbGeAlD
Bosutinib—BMP2K—cerebellum—malignant glioma	0.000194	0.00139	CbGeAlD
Bosutinib—CAMK2G—cerebellum—malignant glioma	0.000194	0.00139	CbGeAlD
Bosutinib—FYN—spinal cord—malignant glioma	0.000194	0.00139	CbGeAlD
Bosutinib—TAOK3—medulla oblongata—malignant glioma	0.000194	0.00139	CbGeAlD
Bosutinib—MAP4K1—brain—malignant glioma	0.000192	0.00138	CbGeAlD
Bosutinib—MAP3K19—brain—malignant glioma	0.000192	0.00138	CbGeAlD
Bosutinib—LRRK2—cerebellum—malignant glioma	0.000192	0.00138	CbGeAlD
Bosutinib—ABL1—brainstem—malignant glioma	0.000192	0.00138	CbGeAlD
Bosutinib—EGFR—cerebellum—malignant glioma	0.000192	0.00138	CbGeAlD
Bosutinib—PTK2B—central nervous system—malignant glioma	0.000191	0.00138	CbGeAlD
Bosutinib—BTK—brain—malignant glioma	0.000191	0.00138	CbGeAlD
Bosutinib—PDGFRB—telencephalon—malignant glioma	0.000191	0.00137	CbGeAlD
Bosutinib—MAP4K5—spinal cord—malignant glioma	0.000189	0.00136	CbGeAlD
Bosutinib—MAP3K3—spinal cord—malignant glioma	0.000189	0.00136	CbGeAlD
Bosutinib—TNK2—brain—malignant glioma	0.000189	0.00136	CbGeAlD
Bosutinib—CSNK1E—central nervous system—malignant glioma	0.000188	0.00135	CbGeAlD
Bosutinib—PTK2B—cerebellum—malignant glioma	0.000187	0.00135	CbGeAlD
Bosutinib—MAP4K2—brain—malignant glioma	0.000186	0.00134	CbGeAlD
Bosutinib—IRAK4—central nervous system—malignant glioma	0.000185	0.00133	CbGeAlD
Bosutinib—SIK1—central nervous system—malignant glioma	0.000185	0.00133	CbGeAlD
Bosutinib—ABL1—retina—malignant glioma	0.000185	0.00133	CbGeAlD
Bosutinib—CSNK1E—cerebellum—malignant glioma	0.000184	0.00132	CbGeAlD
Bosutinib—EPHA4—central nervous system—malignant glioma	0.000184	0.00132	CbGeAlD
Bosutinib—STK3—brain—malignant glioma	0.000183	0.00132	CbGeAlD
Bosutinib—ERBB4—brain—malignant glioma	0.000183	0.00132	CbGeAlD
Bosutinib—ERBB3—central nervous system—malignant glioma	0.000182	0.00131	CbGeAlD
Bosutinib—ULK3—central nervous system—malignant glioma	0.000181	0.0013	CbGeAlD
Bosutinib—MAP2K2—central nervous system—malignant glioma	0.000181	0.0013	CbGeAlD
Bosutinib—IRAK4—cerebellum—malignant glioma	0.000181	0.0013	CbGeAlD
Bosutinib—SIK1—cerebellum—malignant glioma	0.000181	0.0013	CbGeAlD
Bosutinib—ROCK1—brain—malignant glioma	0.000181	0.0013	CbGeAlD
Bosutinib—MAP3K2—central nervous system—malignant glioma	0.00018	0.00129	CbGeAlD
Bosutinib—EPHA4—cerebellum—malignant glioma	0.000179	0.00129	CbGeAlD
Bosutinib—YES1—midbrain—malignant glioma	0.000179	0.00129	CbGeAlD
Bosutinib—ERBB3—cerebellum—malignant glioma	0.000178	0.00128	CbGeAlD
Bosutinib—ULK3—cerebellum—malignant glioma	0.000177	0.00127	CbGeAlD
Bosutinib—MAP2K2—cerebellum—malignant glioma	0.000177	0.00127	CbGeAlD
Bosutinib—TAOK3—midbrain—malignant glioma	0.000177	0.00127	CbGeAlD
Bosutinib—TBK1—central nervous system—malignant glioma	0.000176	0.00127	CbGeAlD
Bosutinib—PTK2—central nervous system—malignant glioma	0.000176	0.00127	CbGeAlD
Bosutinib—MAP3K2—cerebellum—malignant glioma	0.000176	0.00127	CbGeAlD
Bosutinib—BMPR2—brain—malignant glioma	0.000176	0.00126	CbGeAlD
Bosutinib—YES1—spinal cord—malignant glioma	0.000175	0.00126	CbGeAlD
Bosutinib—EPHB3—brain—malignant glioma	0.000175	0.00125	CbGeAlD
Bosutinib—STK36—brain—malignant glioma	0.000175	0.00125	CbGeAlD
Bosutinib—MAP3K7—cerebellum—malignant glioma	0.000174	0.00125	CbGeAlD
Bosutinib—MAP2K5—medulla oblongata—malignant glioma	0.000174	0.00125	CbGeAlD
Bosutinib—TAOK3—spinal cord—malignant glioma	0.000173	0.00124	CbGeAlD
Bosutinib—MERTK—brain—malignant glioma	0.000173	0.00124	CbGeAlD
Bosutinib—PTK2—cerebellum—malignant glioma	0.000172	0.00124	CbGeAlD
Bosutinib—TBK1—cerebellum—malignant glioma	0.000172	0.00124	CbGeAlD
Bosutinib—ABL1—telencephalon—malignant glioma	0.00017	0.00122	CbGeAlD
Bosutinib—RPS6KB1—central nervous system—malignant glioma	0.00017	0.00122	CbGeAlD
Bosutinib—CSF1R—medulla oblongata—malignant glioma	0.000169	0.00122	CbGeAlD
Bosutinib—MAP4K4—brain—malignant glioma	0.000169	0.00122	CbGeAlD
Bosutinib—IRAK1—cerebellum—malignant glioma	0.000169	0.00121	CbGeAlD
Bosutinib—FGR—central nervous system—malignant glioma	0.000169	0.00121	CbGeAlD
Bosutinib—SRC—spinal cord—malignant glioma	0.000168	0.00121	CbGeAlD
Bosutinib—BCR—brain—malignant glioma	0.000168	0.00121	CbGeAlD
Bosutinib—NUAK2—brain—malignant glioma	0.000168	0.00121	CbGeAlD
Bosutinib—AXL—central nervous system—malignant glioma	0.000168	0.00121	CbGeAlD
Bosutinib—MAP3K12—brain—malignant glioma	0.000167	0.0012	CbGeAlD
Bosutinib—RPS6KB1—cerebellum—malignant glioma	0.000166	0.00119	CbGeAlD
Bosutinib—AXL—cerebellum—malignant glioma	0.000164	0.00118	CbGeAlD
Bosutinib—MAP2K1—brain—malignant glioma	0.000164	0.00118	CbGeAlD
Bosutinib—STK35—brain—malignant glioma	0.000164	0.00118	CbGeAlD
Bosutinib—CSK—brain—malignant glioma	0.000162	0.00117	CbGeAlD
Bosutinib—CSNK1A1—brain—malignant glioma	0.000161	0.00116	CbGeAlD
Bosutinib—HCK—brain—malignant glioma	0.00016	0.00115	CbGeAlD
Bosutinib—CLK1—brain—malignant glioma	0.00016	0.00115	CbGeAlD
Bosutinib—ABL2—brain—malignant glioma	0.000159	0.00115	CbGeAlD
Bosutinib—MAP2K5—midbrain—malignant glioma	0.000159	0.00114	CbGeAlD
Bosutinib—SLK—cerebellum—malignant glioma	0.000158	0.00114	CbGeAlD
Bosutinib—EPHA2—central nervous system—malignant glioma	0.000157	0.00113	CbGeAlD
Bosutinib—CAMK2G—brain—malignant glioma	0.000157	0.00113	CbGeAlD
Bosutinib—BMP2K—brain—malignant glioma	0.000157	0.00113	CbGeAlD
Bosutinib—FYN—central nervous system—malignant glioma	0.000157	0.00113	CbGeAlD
Bosutinib—EPHB4—cerebellum—malignant glioma	0.000157	0.00113	CbGeAlD
Bosutinib—LRRK2—brain—malignant glioma	0.000156	0.00112	CbGeAlD
Bosutinib—EGFR—brain—malignant glioma	0.000156	0.00112	CbGeAlD
Bosutinib—CSF1R—midbrain—malignant glioma	0.000155	0.00111	CbGeAlD
Bosutinib—MAP2K5—spinal cord—malignant glioma	0.000155	0.00111	CbGeAlD
Bosutinib—FYN—cerebellum—malignant glioma	0.000154	0.0011	CbGeAlD
Bosutinib—MAP4K5—central nervous system—malignant glioma	0.000154	0.0011	CbGeAlD
Bosutinib—MAP3K3—central nervous system—malignant glioma	0.000154	0.0011	CbGeAlD
Bosutinib—PTK2B—brain—malignant glioma	0.000152	0.00109	CbGeAlD
Bosutinib—CSF1R—spinal cord—malignant glioma	0.000151	0.00109	CbGeAlD
Bosutinib—PDGFRB—medulla oblongata—malignant glioma	0.00015	0.00108	CbGeAlD
Bosutinib—MAP4K5—cerebellum—malignant glioma	0.00015	0.00108	CbGeAlD
Bosutinib—MAP3K3—cerebellum—malignant glioma	0.00015	0.00108	CbGeAlD
Bosutinib—CSNK1E—brain—malignant glioma	0.00015	0.00108	CbGeAlD
Bosutinib—SIK1—brain—malignant glioma	0.000147	0.00106	CbGeAlD
Bosutinib—IRAK4—brain—malignant glioma	0.000147	0.00106	CbGeAlD
Bosutinib—EPHA4—brain—malignant glioma	0.000146	0.00105	CbGeAlD
Bosutinib—ERBB3—brain—malignant glioma	0.000144	0.00104	CbGeAlD
Bosutinib—ULK3—brain—malignant glioma	0.000144	0.00104	CbGeAlD
Bosutinib—MAP2K2—brain—malignant glioma	0.000144	0.00104	CbGeAlD
Bosutinib—MAP3K2—brain—malignant glioma	0.000143	0.00103	CbGeAlD
Bosutinib—YES1—central nervous system—malignant glioma	0.000142	0.00102	CbGeAlD
Bosutinib—MAP3K7—brain—malignant glioma	0.000142	0.00102	CbGeAlD
Bosutinib—STK10—central nervous system—malignant glioma	0.000141	0.00101	CbGeAlD
Bosutinib—TAOK3—central nervous system—malignant glioma	0.00014	0.00101	CbGeAlD
Bosutinib—PTK2—brain—malignant glioma	0.00014	0.00101	CbGeAlD
Bosutinib—TBK1—brain—malignant glioma	0.00014	0.00101	CbGeAlD
Bosutinib—YES1—cerebellum—malignant glioma	0.000139	0.000997	CbGeAlD
Bosutinib—STK10—cerebellum—malignant glioma	0.000137	0.000988	CbGeAlD
Bosutinib—PDGFRB—midbrain—malignant glioma	0.000137	0.000987	CbGeAlD
Bosutinib—IRAK1—brain—malignant glioma	0.000137	0.000987	CbGeAlD
Bosutinib—TAOK3—cerebellum—malignant glioma	0.000137	0.000984	CbGeAlD
Bosutinib—SRC—central nervous system—malignant glioma	0.000136	0.000981	CbGeAlD
Bosutinib—RPS6KB1—brain—malignant glioma	0.000135	0.000968	CbGeAlD
Bosutinib—PDGFRB—spinal cord—malignant glioma	0.000134	0.000963	CbGeAlD
Bosutinib—ABL1—medulla oblongata—malignant glioma	0.000134	0.000962	CbGeAlD
Bosutinib—FGR—brain—malignant glioma	0.000134	0.000962	CbGeAlD
Bosutinib—SRC—cerebellum—malignant glioma	0.000133	0.000959	CbGeAlD
Bosutinib—AXL—brain—malignant glioma	0.000133	0.000959	CbGeAlD
Bosutinib—SLK—brain—malignant glioma	0.000128	0.000923	CbGeAlD
Bosutinib—EPHB4—brain—malignant glioma	0.000127	0.000916	CbGeAlD
Bosutinib—MAP2K5—central nervous system—malignant glioma	0.000126	0.000903	CbGeAlD
Bosutinib—EPHA2—brain—malignant glioma	0.000125	0.000899	CbGeAlD
Bosutinib—FYN—brain—malignant glioma	0.000125	0.000897	CbGeAlD
Bosutinib—MAP2K5—cerebellum—malignant glioma	0.000123	0.000882	CbGeAlD
Bosutinib—CSF1R—central nervous system—malignant glioma	0.000122	0.000881	CbGeAlD
Bosutinib—ABL1—midbrain—malignant glioma	0.000122	0.00088	CbGeAlD
Bosutinib—MAP3K3—brain—malignant glioma	0.000122	0.000877	CbGeAlD
Bosutinib—MAP4K5—brain—malignant glioma	0.000122	0.000877	CbGeAlD
Bosutinib—CSF1R—cerebellum—malignant glioma	0.00012	0.000861	CbGeAlD
Bosutinib—ABL1—spinal cord—malignant glioma	0.000119	0.000858	CbGeAlD
Bosutinib—YES1—brain—malignant glioma	0.000113	0.00081	CbGeAlD
Bosutinib—STK10—brain—malignant glioma	0.000112	0.000802	CbGeAlD
Bosutinib—TAOK3—brain—malignant glioma	0.000111	0.000799	CbGeAlD
Bosutinib—ABCB1—blood vessel—malignant glioma	0.000109	0.000785	CbGeAlD
Bosutinib—PDGFRB—central nervous system—malignant glioma	0.000109	0.000781	CbGeAlD
Bosutinib—SRC—brain—malignant glioma	0.000108	0.000779	CbGeAlD
Bosutinib—PDGFRB—cerebellum—malignant glioma	0.000106	0.000764	CbGeAlD
Bosutinib—MAP2K5—brain—malignant glioma	9.97e-05	0.000717	CbGeAlD
Bosutinib—CSF1R—brain—malignant glioma	9.73e-05	0.000699	CbGeAlD
Bosutinib—ABL1—central nervous system—malignant glioma	9.68e-05	0.000696	CbGeAlD
Bosutinib—ABL1—cerebellum—malignant glioma	9.46e-05	0.000681	CbGeAlD
Bosutinib—PDGFRB—brain—malignant glioma	8.63e-05	0.00062	CbGeAlD
Bosutinib—ABL1—brain—malignant glioma	7.69e-05	0.000553	CbGeAlD
Bosutinib—ABCB1—embryo—malignant glioma	6.51e-05	0.000468	CbGeAlD
Bosutinib—ABCB1—retina—malignant glioma	5.76e-05	0.000414	CbGeAlD
Bosutinib—ABCB1—telencephalon—malignant glioma	5.3e-05	0.000381	CbGeAlD
Bosutinib—CYP3A4—central nervous system—malignant glioma	4.25e-05	0.000306	CbGeAlD
Bosutinib—ABCB1—medulla oblongata—malignant glioma	4.16e-05	0.000299	CbGeAlD
Bosutinib—ABCB1—midbrain—malignant glioma	3.8e-05	0.000274	CbGeAlD
Bosutinib—ABCB1—spinal cord—malignant glioma	3.71e-05	0.000267	CbGeAlD
Bosutinib—ABCB1—central nervous system—malignant glioma	3.01e-05	0.000217	CbGeAlD
Bosutinib—ABCB1—cerebellum—malignant glioma	2.94e-05	0.000212	CbGeAlD
Bosutinib—ABCB1—brain—malignant glioma	2.39e-05	0.000172	CbGeAlD
Bosutinib—SRC—Signaling Pathways—NOTCH1—malignant glioma	6.8e-07	2.65e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KRAS—malignant glioma	6.79e-07	2.65e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—PIK3CA—malignant glioma	6.78e-07	2.65e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—PIK3CA—malignant glioma	6.78e-07	2.65e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—malignant glioma	6.76e-07	2.64e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—PIK3CA—malignant glioma	6.76e-07	2.64e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CASP3—malignant glioma	6.76e-07	2.64e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—malignant glioma	6.75e-07	2.63e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CXCL8—malignant glioma	6.75e-07	2.63e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AKT1—malignant glioma	6.74e-07	2.63e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAT—malignant glioma	6.71e-07	2.62e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—KRAS—malignant glioma	6.71e-07	2.62e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—malignant glioma	6.71e-07	2.62e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CD80—malignant glioma	6.66e-07	2.6e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CG—malignant glioma	6.65e-07	2.6e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—APC—malignant glioma	6.65e-07	2.6e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CXCL8—malignant glioma	6.64e-07	2.59e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—PIK3CA—malignant glioma	6.62e-07	2.58e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—malignant glioma	6.61e-07	2.58e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CXCL8—malignant glioma	6.61e-07	2.58e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CD—malignant glioma	6.6e-07	2.58e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CASP3—malignant glioma	6.6e-07	2.57e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—STAT3—malignant glioma	6.59e-07	2.57e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—PIK3CA—malignant glioma	6.59e-07	2.57e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—malignant glioma	6.59e-07	2.57e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGF—malignant glioma	6.57e-07	2.57e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—malignant glioma	6.56e-07	2.56e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—malignant glioma	6.56e-07	2.56e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—malignant glioma	6.56e-07	2.56e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FGF2—malignant glioma	6.56e-07	2.56e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—KRAS—malignant glioma	6.55e-07	2.56e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—PIK3CA—malignant glioma	6.54e-07	2.55e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTPN11—malignant glioma	6.53e-07	2.55e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—PIK3CA—malignant glioma	6.52e-07	2.54e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—malignant glioma	6.51e-07	2.54e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—STAT3—malignant glioma	6.5e-07	2.54e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PIK3CA—malignant glioma	6.48e-07	2.53e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—malignant glioma	6.48e-07	2.53e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—malignant glioma	6.47e-07	2.53e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CASP3—malignant glioma	6.46e-07	2.52e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—malignant glioma	6.45e-07	2.52e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—malignant glioma	6.41e-07	2.5e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PIK3CA—malignant glioma	6.4e-07	2.5e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—malignant glioma	6.39e-07	2.49e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CASP3—malignant glioma	6.36e-07	2.48e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—STAT3—malignant glioma	6.35e-07	2.48e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PTEN—malignant glioma	6.35e-07	2.48e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—malignant glioma	6.35e-07	2.48e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NCOR1—malignant glioma	6.34e-07	2.47e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—malignant glioma	6.34e-07	2.47e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—malignant glioma	6.33e-07	2.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CASP3—malignant glioma	6.32e-07	2.47e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FGF2—malignant glioma	6.32e-07	2.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—malignant glioma	6.31e-07	2.46e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTEN—malignant glioma	6.29e-07	2.45e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—malignant glioma	6.27e-07	2.45e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—malignant glioma	6.25e-07	2.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—BRAF—malignant glioma	6.25e-07	2.44e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—malignant glioma	6.25e-07	2.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PIK3CA—malignant glioma	6.24e-07	2.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—malignant glioma	6.23e-07	2.43e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTEN—malignant glioma	6.2e-07	2.42e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—malignant glioma	6.19e-07	2.42e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PIK3CA—malignant glioma	6.16e-07	2.41e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MDM2—malignant glioma	6.14e-07	2.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—malignant glioma	6.13e-07	2.39e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTT1—malignant glioma	6.13e-07	2.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—malignant glioma	6.12e-07	2.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RAF1—malignant glioma	6.12e-07	2.39e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—malignant glioma	6.1e-07	2.38e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—STAT3—malignant glioma	6.09e-07	2.38e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT2—malignant glioma	6.08e-07	2.37e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTEN—malignant glioma	6.07e-07	2.37e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—malignant glioma	6.06e-07	2.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—malignant glioma	6.05e-07	2.36e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—malignant glioma	6.04e-07	2.36e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—malignant glioma	6.02e-07	2.35e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—malignant glioma	6.01e-07	2.35e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—malignant glioma	5.98e-07	2.34e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—malignant glioma	5.98e-07	2.33e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTEN—malignant glioma	5.97e-07	2.33e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—malignant glioma	5.97e-07	2.33e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CB—malignant glioma	5.97e-07	2.33e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTEN—malignant glioma	5.94e-07	2.32e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—malignant glioma	5.93e-07	2.31e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MDM2—malignant glioma	5.91e-07	2.31e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—malignant glioma	5.91e-07	2.31e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—malignant glioma	5.91e-07	2.31e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—malignant glioma	5.9e-07	2.3e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RAF1—malignant glioma	5.89e-07	2.3e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CD—malignant glioma	5.84e-07	2.28e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—malignant glioma	5.83e-07	2.28e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—malignant glioma	5.82e-07	2.27e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—malignant glioma	5.8e-07	2.26e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—malignant glioma	5.77e-07	2.25e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CB—malignant glioma	5.75e-07	2.25e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—malignant glioma	5.75e-07	2.25e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS1—malignant glioma	5.74e-07	2.24e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—malignant glioma	5.74e-07	2.24e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—malignant glioma	5.74e-07	2.24e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—malignant glioma	5.74e-07	2.24e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—malignant glioma	5.68e-07	2.22e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—malignant glioma	5.66e-07	2.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—malignant glioma	5.66e-07	2.21e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—malignant glioma	5.63e-07	2.2e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—malignant glioma	5.63e-07	2.2e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—malignant glioma	5.62e-07	2.19e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—malignant glioma	5.6e-07	2.18e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF2—malignant glioma	5.6e-07	2.18e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—malignant glioma	5.58e-07	2.18e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—malignant glioma	5.55e-07	2.17e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—malignant glioma	5.54e-07	2.16e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—malignant glioma	5.54e-07	2.16e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—malignant glioma	5.54e-07	2.16e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—malignant glioma	5.53e-07	2.16e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—malignant glioma	5.53e-07	2.16e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—malignant glioma	5.52e-07	2.16e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—malignant glioma	5.49e-07	2.14e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—malignant glioma	5.48e-07	2.14e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—malignant glioma	5.48e-07	2.14e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—malignant glioma	5.45e-07	2.13e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—malignant glioma	5.44e-07	2.13e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—malignant glioma	5.43e-07	2.12e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—malignant glioma	5.43e-07	2.12e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—malignant glioma	5.41e-07	2.11e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—malignant glioma	5.39e-07	2.11e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—malignant glioma	5.38e-07	2.1e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—malignant glioma	5.37e-07	2.09e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—malignant glioma	5.34e-07	2.09e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—malignant glioma	5.34e-07	2.09e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—BCHE—malignant glioma	5.34e-07	2.08e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—malignant glioma	5.32e-07	2.08e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—malignant glioma	5.31e-07	2.07e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—malignant glioma	5.3e-07	2.07e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—malignant glioma	5.29e-07	2.07e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—malignant glioma	5.29e-07	2.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—malignant glioma	5.28e-07	2.06e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC5A5—malignant glioma	5.27e-07	2.06e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—malignant glioma	5.27e-07	2.06e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MDM2—malignant glioma	5.24e-07	2.04e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—malignant glioma	5.23e-07	2.04e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—malignant glioma	5.23e-07	2.04e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—malignant glioma	5.22e-07	2.04e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RAF1—malignant glioma	5.22e-07	2.04e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—malignant glioma	5.2e-07	2.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—malignant glioma	5.19e-07	2.03e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAV1—malignant glioma	5.16e-07	2.02e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—malignant glioma	5.16e-07	2.02e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—malignant glioma	5.16e-07	2.01e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—malignant glioma	5.16e-07	2.01e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—malignant glioma	5.15e-07	2.01e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—malignant glioma	5.13e-07	2e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—malignant glioma	5.11e-07	1.99e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—malignant glioma	5.1e-07	1.99e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—malignant glioma	5.09e-07	1.99e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—malignant glioma	5.04e-07	1.97e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—malignant glioma	5.04e-07	1.97e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—malignant glioma	5.03e-07	1.97e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—malignant glioma	5.01e-07	1.96e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—malignant glioma	5e-07	1.95e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—malignant glioma	4.97e-07	1.94e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—malignant glioma	4.96e-07	1.94e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—malignant glioma	4.96e-07	1.94e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—malignant glioma	4.94e-07	1.93e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—malignant glioma	4.93e-07	1.92e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—malignant glioma	4.92e-07	1.92e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—malignant glioma	4.9e-07	1.91e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—malignant glioma	4.89e-07	1.91e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—malignant glioma	4.88e-07	1.9e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—malignant glioma	4.85e-07	1.9e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—malignant glioma	4.83e-07	1.88e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—malignant glioma	4.83e-07	1.88e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—malignant glioma	4.8e-07	1.88e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—malignant glioma	4.76e-07	1.86e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—malignant glioma	4.75e-07	1.86e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—malignant glioma	4.7e-07	1.84e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—malignant glioma	4.69e-07	1.83e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—malignant glioma	4.69e-07	1.83e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—malignant glioma	4.68e-07	1.83e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—malignant glioma	4.66e-07	1.82e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—malignant glioma	4.66e-07	1.82e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—malignant glioma	4.61e-07	1.8e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—malignant glioma	4.6e-07	1.8e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—malignant glioma	4.59e-07	1.79e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—malignant glioma	4.56e-07	1.78e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—malignant glioma	4.54e-07	1.77e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—malignant glioma	4.49e-07	1.75e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—malignant glioma	4.48e-07	1.75e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—malignant glioma	4.45e-07	1.74e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—malignant glioma	4.45e-07	1.74e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—malignant glioma	4.43e-07	1.73e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—malignant glioma	4.43e-07	1.73e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—malignant glioma	4.43e-07	1.73e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—malignant glioma	4.4e-07	1.72e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—malignant glioma	4.37e-07	1.71e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—malignant glioma	4.33e-07	1.69e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—malignant glioma	4.29e-07	1.67e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—malignant glioma	4.28e-07	1.67e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—malignant glioma	4.25e-07	1.66e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—malignant glioma	4.25e-07	1.66e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—malignant glioma	4.23e-07	1.65e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—malignant glioma	4.21e-07	1.64e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—malignant glioma	4.19e-07	1.64e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—malignant glioma	4.19e-07	1.63e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—malignant glioma	4.14e-07	1.62e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—malignant glioma	4.14e-07	1.61e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAT—malignant glioma	4.13e-07	1.61e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—malignant glioma	4.13e-07	1.61e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—malignant glioma	4.09e-07	1.6e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—malignant glioma	4.08e-07	1.59e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—malignant glioma	4.05e-07	1.58e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—malignant glioma	4.04e-07	1.58e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—malignant glioma	3.98e-07	1.55e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—malignant glioma	3.96e-07	1.55e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—malignant glioma	3.94e-07	1.54e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—malignant glioma	3.92e-07	1.53e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOR1—malignant glioma	3.9e-07	1.52e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—malignant glioma	3.82e-07	1.49e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—malignant glioma	3.66e-07	1.43e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—malignant glioma	3.66e-07	1.43e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—malignant glioma	3.64e-07	1.42e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—malignant glioma	3.62e-07	1.41e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—malignant glioma	3.6e-07	1.41e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—malignant glioma	3.58e-07	1.4e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—malignant glioma	3.57e-07	1.39e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—malignant glioma	3.57e-07	1.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—malignant glioma	3.52e-07	1.37e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—malignant glioma	3.51e-07	1.37e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—malignant glioma	3.5e-07	1.36e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—malignant glioma	3.44e-07	1.34e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—malignant glioma	3.42e-07	1.34e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—malignant glioma	3.39e-07	1.32e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—malignant glioma	3.38e-07	1.32e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAV1—malignant glioma	3.18e-07	1.24e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—malignant glioma	3.11e-07	1.22e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—malignant glioma	3.11e-07	1.21e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—malignant glioma	3e-07	1.17e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—malignant glioma	2.97e-07	1.16e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.9e-07	1.13e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—malignant glioma	2.87e-07	1.12e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—malignant glioma	2.8e-07	1.09e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.55e-07	9.95e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—malignant glioma	2.54e-07	9.9e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.22e-07	8.67e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—malignant glioma	2.2e-07	8.59e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—malignant glioma	2.2e-07	8.58e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—malignant glioma	1.92e-07	7.49e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—malignant glioma	1.8e-07	7.01e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.35e-07	5.28e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—malignant glioma	1.11e-07	4.32e-07	CbGpPWpGaD
